Pulmonx Corporation Debt to Equity Ratio 2019-2024 | LUNG
Current and historical debt to equity ratio values for Pulmonx Corporation (LUNG) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Pulmonx Corporation debt/equity for the three months ending September 30, 2024 was 0.40.
| Pulmonx Corporation Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $0.07B | $0.09B | 0.78 |
| 2024-06-30 | $0.07B | $0.10B | 0.71 |
| 2024-03-31 | $0.05B | $0.11B | 0.49 |
| 2023-12-31 | $0.06B | $0.12B | 0.50 |
| 2023-09-30 | $0.06B | $0.13B | 0.47 |
| 2023-06-30 | $0.06B | $0.13B | 0.44 |
| 2023-03-31 | $0.06B | $0.14B | 0.40 |
| 2022-12-31 | $0.04B | $0.15B | 0.26 |
| 2022-09-30 | $0.04B | $0.16B | 0.24 |
| 2022-06-30 | $0.04B | $0.17B | 0.24 |
| 2022-03-31 | $0.04B | $0.18B | 0.22 |
| 2021-12-31 | $0.04B | $0.19B | 0.22 |
| 2021-09-30 | $0.04B | $0.20B | 0.22 |
| 2021-06-30 | $0.04B | $0.21B | 0.19 |
| 2021-03-31 | $0.04B | $0.22B | 0.18 |
| 2020-12-31 | $0.04B | $0.23B | 0.17 |
| 2020-09-30 | $0.28B | $-0.21B | -1.34 |
| 2020-06-30 | $0.00B | $0.00B | 0.00 |
| 2020-03-31 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.00B | 0.00 | |
| 2019-09-30 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.04B | $-0.03B | -1.56 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MEDICAL INFO SYS | $0.354B | $0.084B |
| Pulmonx Corporation is a medical technology company. It designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. Pulmonx Corporation is based in Redwood City, California. | |||